Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymyxin E sodium mesylate for carbapenem-resistant gram-negative bacterial infection in critically ill adults
ChiCTR2500103466Phase 4Recruiting
- Sponsor
- Hangzhou Linping Hospital of Traditional Chinese Medicine
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of colistimethate sodium in Gram-negative bacterial infection (2 arms), sponsored by Hangzhou Linping Hospital of Traditional Chinese Medicine. Primary endpoints: White blood cell count, Neutrophil percentage and 7 more. Started May 2025; status: recruiting.
02
Drugs
colistimethate sodium
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR2500103466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103466.